Trials / Completed
CompletedNCT00412867
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke （Japan Alteplase Clinical Trial Ⅱ：J-ACT Ⅱ）
Post-marketing Clinical Study of Alteplase for Acute Ischemic Stroke (Phase 4)
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to confirm the efficacy and safety of intravenously administered alteplase in patients with acute ischemic stroke based on the rate of recanalization assessed by magnetic resonance angiography (MRA), the rate of patients with a modified Rankin Scale (mRS) score of 0-1, and the incidence of symptomatic intracranial hemorrhage (sICH), in comparison with the data reported in the current literature.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Alteplase | 0.6 mg/kg of Alteplase is intravenously administered |
Timeline
- Start date
- 2006-12-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-12-19
- Last updated
- 2026-01-05
- Results posted
- 2012-02-24
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT00412867. Inclusion in this directory is not an endorsement.